ATOS

Atossa Therapeutics (ATOS)

Atossa Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ATOS

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/15	21 : 30	GlobeNewswire Inc.	Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/05/15	05 : 46	Edgar (US Regulatory)	Form DEL AM - Delaying amendment	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/05/14	05 : 05	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/05/13	22 : 05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/05/13	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/05/13	21 : 50	GlobeNewswire Inc.	Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/05/10	22 : 04	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/05/10	22 : 00	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/05/07	21 : 30	GlobeNewswire Inc.	Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/04/29	21 : 30	GlobeNewswire Inc.	Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/04/15	21 : 30	GlobeNewswire Inc.	Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/04/11	21 : 30	GlobeNewswire Inc.	Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/04/10	00 : 59	GlobeNewswire Inc.	Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/04/02	05 : 00	GlobeNewswire Inc.	Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/03/19	21 : 30	GlobeNewswire Inc.	Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/03/18	21 : 30	GlobeNewswire Inc.	Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/03/12	21 : 30	GlobeNewswire Inc.	Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/02/22	22 : 30	GlobeNewswire Inc.	Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/02/07	22 : 30	GlobeNewswire Inc.	Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial	NASDAQ:ATOS	Atossa Therapeutics Inc
2024/01/09	22 : 30	GlobeNewswire Inc.	Atossa Therapeutics Issues Letter to Shareholders	NASDAQ:ATOS	Atossa Therapeutics Inc
2023/12/04	22 : 30	GlobeNewswire Inc.	Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director	NASDAQ:ATOS	Atossa Therapeutics Inc
2023/11/20	22 : 30	GlobeNewswire Inc.	Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial	NASDAQ:ATOS	Atossa Therapeutics Inc
2023/11/16	07 : 03	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:ATOS	Atossa Therapeutics Inc
2023/11/16	06 : 15	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ATOS	Atossa Therapeutics Inc
2023/11/16	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ATOS	Atossa Therapeutics Inc
2023/11/13	23 : 10	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ATOS	Atossa Therapeutics Inc
2023/11/13	23 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ATOS	Atossa Therapeutics Inc
2023/11/13	23 : 00	GlobeNewswire Inc.	Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:ATOS	Atossa Therapeutics Inc
2023/11/09	23 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ATOS	Atossa Therapeutics Inc
2023/11/09	23 : 00	GlobeNewswire Inc.	Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors	NASDAQ:ATOS	Atossa Therapeutics Inc